NASDAQ:NMTR 9 Meters Biopharma - NMTR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.32 +0.01 (+0.76%) (As of 03/24/2023 01:39 PM ET) Add Compare Share Share Today's Range$1.31▼$1.3450-Day Range$1.31▼$2.6152-Week Range$1.00▼$13.20Volume11,826 shsAverage Volume104,928 shsMarket Capitalization$17.09 millionP/E RatioN/ADividend YieldN/APrice Target$20.85 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media 9 Meters Biopharma MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside3,246.6% Upside$44.18 Price TargetShort InterestHealthy3.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.48Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.28) to ($3.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector488th out of 989 stocksPharmaceutical Preparations Industry228th out of 480 stocks 3.3 Analyst's Opinion Consensus Rating9 Meters Biopharma has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.18, 9 Meters Biopharma has a forecasted upside of 3,246.6% from its current price of $1.32.Amount of Analyst Coverage9 Meters Biopharma has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.13% of the float of 9 Meters Biopharma has been sold short.Short Interest Ratio / Days to Cover9 Meters Biopharma has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 9 Meters Biopharma has recently decreased by 7.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend Yield9 Meters Biopharma does not currently pay a dividend.Dividend Growth9 Meters Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NMTR. Previous Next 1.4 News and Social Media Coverage News Sentiment9 Meters Biopharma has a news sentiment score of -0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for 9 Meters Biopharma this week, compared to 0 articles on an average week.Search InterestOnly 12 people have searched for NMTR on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat Follows10 people have added 9 Meters Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 9 Meters Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of 9 Meters Biopharma is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for 9 Meters Biopharma are expected to grow in the coming year, from ($3.28) to ($3.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 9 Meters Biopharma is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 9 Meters Biopharma is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio9 Meters Biopharma has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 9 Meters Biopharma (NASDAQ:NMTR) Stock9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.Read More Receive NMTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NMTR Stock News HeadlinesMarch 24, 2023 | americanbankingnews.com9 Meters Biopharma's (NMTR) "Buy" Rating Reaffirmed at Brookline Capital ManagementMarch 22, 2023 | benzinga.com9 Meters Biopharma Stock (NASDAQ:NMTR), Guidance and ForecastMarch 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 20, 2023 | americanbankingnews.com9 Meters Biopharma (NASDAQ:NMTR) Stock Rating Lowered by Truist FinancialMarch 20, 2023 | americanbankingnews.com9 Meters Biopharma (NMTR) Set to Announce Quarterly Earnings on TuesdayMarch 16, 2023 | bizjournals.comRaleigh pharma raises $5M as phase 3 study beginsMarch 15, 2023 | finance.yahoo.com9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 14, 2023 | finance.yahoo.com9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq RulesMarch 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 7, 2023 | finance.yahoo.com9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare ConferenceJanuary 31, 2023 | finance.yahoo.com9 Meters Biopharma to Present at the 2023 BIO CEO & Investor ConferenceNovember 29, 2022 | finance.yahoo.com9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel SyndromeNovember 14, 2022 | finance.yahoo.com9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave RoussyNovember 8, 2022 | finance.yahoo.com9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022October 24, 2022 | finance.yahoo.com9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific MeetingOctober 18, 2022 | bizjournals.com9 Meters Biopharma triggers reverse stock split to maintain Nasdaq listingOctober 18, 2022 | finance.yahoo.com9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific MeetingOctober 17, 2022 | finance.yahoo.com9 Meters Biopharma Announces 1-for-20 Reverse Stock SplitSeptember 27, 2022 | seekingalpha.com9 Meters Biopharma gains after mid-stage data for short bowel syndrome drugSeptember 26, 2022 | finance.yahoo.com9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel SyndromeSeptember 6, 2022 | finance.yahoo.com9 Meters Biopharma to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 1, 2022 | finance.yahoo.com9 Meters Biopharma to Participate at the 44th European Society for Clinical Nutrition and Metabolism (ESPEN) CongressAugust 31, 2022 | finance.yahoo.com9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma ConferenceAugust 13, 2022 | uk.finance.yahoo.com9 Meters Biopharma, Inc. (NMTR)July 6, 2022 | finance.yahoo.com9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022July 5, 2022 | bizjournals.comRaleigh drugmaker shifts focus after trial setbackJune 30, 2022 | seekingalpha.com9 Meters stock falls despite drug showing promise in short bowel syndrome trialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NMTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 9 Meters Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NMTR Company Calendar Last Earnings11/15/2021Today3/24/2023Next Earnings (Estimated)3/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NMTR CUSIPN/A CIK1551986 Webwww.9meters.com Phone(919) 275-1933FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price Forecast$44.18 High Stock Price Forecast$100.00 Low Stock Price Forecast$1.70 Forecasted Upside/Downside+1,491.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-153.18% Return on Assets-101.53% Debt Debt-to-Equity Ratio1.17 Current Ratio1.43 Quick Ratio1.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.25 per share Price / Book0.40Miscellaneous Outstanding Shares12,950,000Free Float12,644,000Market Cap$16.96 million OptionableOptionable Beta0.51 Key ExecutivesJohn TemperatoPresident, Chief Executive Officer & DirectorSireesh AppajosyulaSVP-Corporate Development & OperationsBethany L. SensenigChief Financial & Accounting OfficerPatrick H. GriffinChief Medical OfficerSarah LiuChief Commercial OfficerKey CompetitorsComera Life SciencesNASDAQ:CMRAChemomab TherapeuticsNASDAQ:CMMBAdamis PharmaceuticalsNASDAQ:ADMPInfinity PharmaceuticalsNASDAQ:INFINeuroSense TherapeuticsNASDAQ:NRSNView All CompetitorsInsiders & InstitutionsLaurion Capital Management LPSold 4,330,290 shares on 2/15/2023Ownership: 1.760%Millennium Management LLCSold 918,791 shares on 2/15/2023Ownership: 0.310%Two Sigma Investments LPSold 812,786 shares on 2/14/2023Ownership: 0.368%Susquehanna International Group LLPSold 81,600 shares on 2/14/2023Ownership: 0.000%Renaissance Technologies LLCSold 1,589,032 shares on 2/13/2023Ownership: 0.565%View All Insider TransactionsView All Institutional Transactions NMTR Stock - Frequently Asked Questions Should I buy or sell 9 Meters Biopharma stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 9 Meters Biopharma in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NMTR shares. View NMTR analyst ratings or view top-rated stocks. What is 9 Meters Biopharma's stock price forecast for 2023? 6 brokers have issued 12-month price targets for 9 Meters Biopharma's stock. Their NMTR share price forecasts range from $1.70 to $100.00. On average, they anticipate the company's stock price to reach $44.18 in the next twelve months. This suggests a possible upside of 3,272.1% from the stock's current price. View analysts price targets for NMTR or view top-rated stocks among Wall Street analysts. How have NMTR shares performed in 2023? 9 Meters Biopharma's stock was trading at $1.26 at the beginning of 2023. Since then, NMTR stock has increased by 4.0% and is now trading at $1.31. View the best growth stocks for 2023 here. When is 9 Meters Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023. View our NMTR earnings forecast. How were 9 Meters Biopharma's earnings last quarter? 9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.26. When did 9 Meters Biopharma's stock split? 9 Meters Biopharma shares reverse split on Tuesday, October 18th 2022. The 1-20 reverse split was announced on Tuesday, October 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of 9 Meters Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other 9 Meters Biopharma investors own include Acasti Pharma (ACST), Miragen Therapeutics (MGEN), Bionano Genomics (BNGO), Evofem Biosciences (EVFM), Outlook Therapeutics (OTLK), Tonix Pharmaceuticals (TNXP), Alibaba Group (BABA), Cellectar Biosciences (CLRB), Pfizer (PFE) and Soleno Therapeutics (SLNO). What is 9 Meters Biopharma's stock symbol? 9 Meters Biopharma trades on the NASDAQ under the ticker symbol "NMTR." Who are 9 Meters Biopharma's major shareholders? 9 Meters Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Laurion Capital Management LP (1.76%), GSA Capital Partners LLP (0.85%), Geode Capital Management LLC (0.84%), Renaissance Technologies LLC (0.57%), Two Sigma Investments LP (0.37%) and ODonnell Financial Services LLC (0.34%). Insiders that own company stock include Edward J Sitar, Israel Gp Ltd Orbimed, John Temperato, Mark A Sirgo and Michael T Constantino. View institutional ownership trends. How do I buy shares of 9 Meters Biopharma? Shares of NMTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 9 Meters Biopharma's stock price today? One share of NMTR stock can currently be purchased for approximately $1.31. How much money does 9 Meters Biopharma make? 9 Meters Biopharma (NASDAQ:NMTR) has a market capitalization of $16.96 million. The company earns $-36,780,000.00 in net income (profit) each year or ($3.12) on an earnings per share basis. How can I contact 9 Meters Biopharma? 9 Meters Biopharma's mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The official website for the company is www.9meters.com. The company can be reached via phone at (919) 275-1933 or via email at investor-relations@9meters.com. This page (NASDAQ:NMTR) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.